Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as albuterol aerosol by HFA MDI
albuterol by HFA MDI · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Albuterol HFA BOI | EXPERIMENTAL | - |
| Albuterol HFA MDI | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| albuterol aerosol by HFA MDI | DRUG | albuterol HFA MDI 160 mcg |
| albuterol aerosol by HFA BOI | DRUG | albuterol HFA BOI 160 mcg |
| placebo aerosol by HFA | DRUG | placebo HFA |
Inclusion Criteria: * Provide written informed consent * Male or non-pregnant, non-nursing females aged 12 40 years, inclusive, at the first screening visit * Have exercise-induced bronchospasm (EIB), with or without asthma, as demonstrated by a ≥15% decrease in pre-challenge absolute FEV1 observed...
Albuterol by HFA MDI is an inhaled bronchodilator studied for exercise-induced bronchospasm, a narrowing of the airways triggered by physical activity. It is delivered as an aerosol through a hydrofluoroalkane metered-dose inhaler and is being developed for the respiratory therapeutic area.
Albuterol by HFA MDI works as an agonist at ADRB2, the beta-2 adrenergic receptor. Binding to this receptor relaxes the smooth muscle surrounding the airways, which helps open them and relieve the bronchoconstriction that occurs during exercise-induced bronchospasm.
Albuterol by HFA MDI is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva is the sponsor behind the clinical program for this inhaled bronchodilator in exercise-induced bronchospasm.
Albuterol by HFA MDI is in Phase 3 development. It is an investigational small molecule and has not been established as approved for marketing. The Phase 3 trial in its program has been completed.
Albuterol by HFA MDI has been studied in one completed Phase 3 trial, NCT00085774, titled Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma. That randomized, double-blind, placebo-controlled trial enrolled 24 participants in the United States, ages 12 and older.
Yes. Albuterol by HFA MDI is also known as albuterol aerosol by HFA MDI. Both names refer to the same hydrofluoroalkane metered-dose inhaler formulation of albuterol developed by Teva Pharmaceutical Industries Limited for exercise-induced bronchospasm.